Consecutive daily administration of intratracheal surfactant and human umbilical cord-derived mesenchymal stem cells attenuates hyperoxia-induced lung injury in neonatal rats.

Hsiu-Chu ChouChien-Hsiang ChangChien-Han ChenWillie LinChung-Ming Chen

Published in: Stem cell research & therapy (2021)

Consecutive daily administration of intratracheal surfactant and hUC-MSCs can be an effective regimen for treating hyperoxia-induced lung injury in neonates.

Keyphrases

umbilical cord
mesenchymal stem cells
high glucose
endothelial cells
diabetic rats
physical activity
drug induced
oxidative stress
low birth weight
preterm birth